Breaking the metabolo-immune cycle in primary biliary cholangitis for therapeutic benefit

Read full text Summarise with VIRAT
Authors: Song Yan, Hui Wang, Shiyu Du, Yuqing Li, Di Yang, Min Xu, Qinglong Jin
Cited by: 0
References: 110

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by cholestasis-driven bile duct injury and fibrosis. Biliary epithelial cells (BECs) play a central role in both bile homeostasis and immune regulation, and their metabolic and immune dysfunction is critical in PBC pathogenesis. Furthermore, systemic metabolic disturbances, such as gut dysbiosis, contribute to disease progression. This paper systematically examines the interplay between BEC metabolism-including bile acid imbalance and lipotoxicity-and immune dysregulation, such as autoantigen exposure and Th1/Th17 responses, highlighting how these interactions fuel a self-sustaining "metabolo-immune-fibrosis" cycle in PBC. Current and emerging therapies are also reviewed, emphasizing that future management should move beyond single-pathway targeting and pursue combination strategies capable of simultaneously modulating metabolic, inflammatory, and immune networks.

Fields of Study & Subjects

Liver Diseases and Immunity Drug Transport and Resistance Mechanisms Pediatric Hepatobiliary Diseases and Treatments

Publication details

Journal / source
Frontiers in Immunology
Volume
17
Pages
1766177–1766177
Publication date
25 March 2026
Language
EN